Incidence of Irvine Gass Syndrome after Phacoemulsification with Spectral-Domain Optical Coherence Tomography

ABSTRACT

Purpose: Incidence of significant and non-significant macular edema found using spectral-domain optical coherence tomography (SD-OCT) following cataract surgery.

Methods: Prospective, cohort series conducted at the Croix Rousse University Hospital. Significant macular edema (SME) was defined as the presence of fluid with an increase of 30% or more in central subfield macular thickness compared to baseline on SD-OCT at 6 weeks and non-significant macula edema (NSME) as an increase of less than 30%.

Results: Nine hundred and twenty-eight eyes in 638 patients were included in the study. Incidence of Irvine Gass (IG) syndrome was 9%, 2.3% of patients presented SME, 6.8% NSME. Epiretinal membrane, diabetes, and capsular rupture were significantly associated with a risk of IG. The risk of developing IG in the fellow eye was 23% in cases of IG in the first eye. In total 8.4% of all included patients developed chronic IG (duration of more than 6 months).

Conclusion: This study reports the incidence of IG during 6 months of surgical activity at a French university hospital center.

Keywords:

• Incidence
• macular edema
• optical coherence tomography

Conflicts of interest

David Bellocq declared no conflicts of interest. Thibaud Mathis declared no conflicts of interest. Nicolas Voirin, EPIMOD, is an independent biostatistician paid by Acropol, a non-profit organization (L. Kodjikian), is or has been consulting for Hospices Civils de Lyon, ECDC (European Centre for Disease Prevention and Control), Sanofi Pasteur, Sanofi Pasteur MSD, Allergan, Santen et MedDay. Zainab Machkour-Bentaleb declared no conflicts of interest. Rebacca Sallit declared no conflicts of interest. Philippe Denis: Principal Investigator for trials sponsored by Théa, Alcon, Allergan; has sat on advisory boards for Théa, Alcon, Allergan, lecture fees from Alcon, Alimera, Allergan, Bayer, Théa. Laurent Kodjikian: Principal Investigator for trials sponsored by Novartis, Allergan, Bayer, Théa, Alcon; has sat on advisory boards for Alcon, Alimera, Allergan, Bayer, Roche, Novartis; lecture fees from Alcon, Alimera, Allergan, Bayer, Horus, Novartis, Théa.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Author contributions

DB and LK were the principal investigators who conceived and designed the study. NV was the trial statistician and conducted the analyses. DB, LK, TM, RS, ZMB and PD participated in patient recruitment. This manuscript was drafted by DB, revised by TM and LK and approved by all authors.

Supplementary material

Supplemental data for this article can be accessed on the publisher’s website.

Additional information

Funding

This research received no specific grants from any funding agencies in the public, commercial or not-for-profit sectors.